Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Estudio de provocación de dosis única, controlado con placebo de gaboxadol en hombres adultos con síndrome de X frágil (FXS)

8 de septiembre de 2026 actualizado por: Craig Erickson

This is a single dose, placebo-controlled study. Male subjects aged 18 to 40 years (inclusive) with a diagnosis of FXS. Eligible subjects may enroll in this study comprised of two in home and two in clinic visits each 14 days apart, for a total of four visits. Subjects will be given single dose gaboxadol (10 mg) or matched placebo at each of these visits to take orally. Thus, all enrolled subjects will receive placebo at home and in clinic and receive gaboxadol at home and in clinic in a blinded fashion.

Descripción general del estudio

Estado

Terminado

Condiciones

Intervención / Tratamiento

Tipo de estudio

Intervencionista

Inscripción (Actual)

10

Fase

  • Fase 2

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Ohio
      • Cincinnati, Ohio, Estados Unidos, 45229
        • Cincinnati Children's Hospital Medical Center

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 40 años (Adulto)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Masculino

Descripción

Inclusion Criteria:

  1. Subject consents to participate, or if they are not their own legal guardian, offers assent supported by legally authorized representative consent
  2. Subject is willing and able to comply with the study procedures as specified in the protocol and to comply with the study drug administration. Caregiver also commits to the study requirements prior to any study-related procedures
  3. Subject and caregiver are both able to understand the spoken national language clearly and caregiver can read and write to complete study assessments
  4. Males age 18 to 40 years (inclusive)
  5. Has FXS with molecular genetic confirmation of the full FMR1 mutation (>200 cysteine-guanine-guanine [CGG] repeats). May have been confirmed historically or at Screening
  6. Is in general good health as deemed by the Investigator, determined by physical examination, medical history, and laboratory tests
  7. If receiving serotonin-selective reuptake inhibitor (SSRI), serotonin-norepinephrine reuptake inhibitor (SNRI), or serotonin antagonist and reuptake inhibitor (SARI), is on a stable, well-tolerated dose for the previous 3 months with no further changes anticipated
  8. Is not sexually active or can confirm at least one form of contraceptive

Exclusion Criteria:

  1. Any chronic major medical comorbid condition deemed by the Investigator as presenting added risk to the subject, including but not limited to, refractory hypertension, kidney disease, or liver disease
  2. Diagnosed with diabetes (Type 1 or II) or receiving any anti-diabetic medication
  3. Unstable seizure disorder, defined by any seizure within 6 months prior to baseline visit and/or a change in any anti-convulsant drug dosing in the 60 days prior to study consent
  4. Changes in psychotropic or anti-convulsant (where taken for reasons other than seizure control) drug treatment within 30 days prior to Screening
  5. Significant changes in any educational, behavioral, and/or dietary interventions the month prior to Screening
  6. Planned initiation of new, or modification of ongoing, interventions during the study
  7. Unable or unwilling to take oral medication (whole capsule, despite assistance with a spoonful of applesauce, yoghurt, or equivalent liquid food)
  8. Consumption of liver enzyme inducers or inhibitors including and not limited to foods, medicines, herbal remedies and supplements three days prior to any Visit. Foods or beverages containing CYP3A4/5 inhibitors (e.g., grapefruit, pomegranate, pomelo, and star fruit) should be avoided before taking study medication and for up to 1 hour post dose throughout the study
  9. Has abnormal baseline laboratory assessments including, but not limited to, alanine aminotransferase (ALT) or aspartate aminotransferase (AST) or total bilirubin >1.5 × the upper limit of normal (ULN), serum creatinine >1.5 x ULN or other clinically relevant laboratory abnormality
  10. Has a clinically significant heart rate or blood pressure (BP) at Screening as judged by the Investigator
  11. Has received an investigational drug in any prior clinical study within 30 days or 5 half-lives (whichever is longer) prior to Screening

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Ciencia básica
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación cruzada
  • Enmascaramiento: Cuadruplicar

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Placebo in lab, Gaboxadol in home, Gaboxadol in lab, Placebo in home

Individuals in this condition received Placebo in lab, Gaboxadol in home, Gaboxadol in lab, then Placebo in home.

Drug: Gaboxadol 10 mg as a single dose (two 5mg capsules)

Two placebo capsules

Experimental: Gaboxadol in lab, Gaboxadol in home, Placebo in lab, Placebo in home

Individuals in this condition received Gaboxadol in lab, Gaboxadol in home, Placebo in lab, then Placebo in home.

Drug: Gaboxadol 10 mg as a single dose (two 5mg capsules)

Two placebo capsules

Experimental: Placebo in lab, Placebo in home, Gaboxadol in lab, Gaboxadol in home

Individuals in this condition received Placebo in lab, Placebo in home, Gaboxadol in lab, then Gaboxadol in home.

Drug: Gaboxadol 10 mg as a single dose (two 5mg capsules)

Two placebo capsules

Experimental: Gaboxadol in lab, Placebo in home, Placebo in lab, Gaboxadol in home

Individuals in this condition received Gaboxadol in lab, Placebo in home, Placebo in lab, then Gaboxadol in home.

Drug: Gaboxadol 10 mg as a single dose (two 5mg capsules)

Two placebo capsules

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Target Engagement of Gaboxadol Treatment on EEG Power
Periodo de tiempo: Pre-dose compared to 60 minutes post-dose on 4 study visits, up to day 42

Changes in EEG recordings with gaboxadol treatment (assessed at pre-dose, 60 minutes post-dose, average response across home and lab reported). compared with pre-dose on resting theta, alpha and gamma band absolute power. Absolute power measures reflect the median power averaged across 129 electrodes in μV²/Hz. Means are presented using the average of home and lab values.

Pre-dose compared to 60 minutes post-dose on 4 study visits, up to day 42
Target Engagement of Gaboxadol Treatment on Auditory Chirp
Periodo de tiempo: Pre-dose compared to 60 minutes post-dose on 4 study visits, up to day 42

Changes in EEG recordings with gaboxadol treatment (60-90 minutes post-dose compared with pre-dose on brain response to auditory chirp stimuli), as measured by intertrial phase coherence (ITC). Means are presented using the average of home and lab values.

Pre-dose compared to 60 minutes post-dose on 4 study visits, up to day 42

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
To Investigate the Feasibility of Home Research Visits and Procedures in Adult Males With FXS
Periodo de tiempo: Pre-dose, 60 minutes post-dose

Quality and test-retest reliability of assessments performed at home compared with the hospital setting. This includes blood testing for Fragile X messenger ribonucleoprotein (FMRP: range of 0-40 picomolar) and eye-tracking of eye gaze to eye regions when viewing faces (range of value from 0 percent to 100 percent; higher values are associated with a neurotypical phenotype).

Pre-dose, 60 minutes post-dose
To Investigate the Feasibility of High Density EEG Recording at Home in Adult Males With FXS
Periodo de tiempo: Pre-dose, across four sessions (2 in-lab, 2 in-home), up to day 42

This endpoint examined the reliability of pre-dose resting-state EEG absolute power estimates between in-lab and in-home assessments using intraclass correlation (ICC). ICCs were calculated separately for 129 electrodes using absolute power estimates (μV²/Hz). The reported ICC represents the mean ICC across electrodes, with the standard deviation reflecting variability in ICC values across electrodes. whole-head, pre-dose resting state EEG power estimates from data collected in-lab vs in-home using intraclass correlation (ICC).

Pre-dose, across four sessions (2 in-lab, 2 in-home), up to day 42
To Potentially Explore the Pharmacokinetics of Gaboxadol Treatment in Single-dose Trial Design
Periodo de tiempo: Sixty minutes post-dose on 4 study visits, up to day 42

PK profile (the level of gaboxadol in human plasma) will be obtained at 60 +/- 10 minutes post-dose only).

Sixty minutes post-dose on 4 study visits, up to day 42
To Investigate the Effect of Gaboxadol Treatment on Neuropsychological Assessments
Periodo de tiempo: Pre-dose compared to 60 minutes post-dose on 4 study visits, up to day 42

Changes in cognitive and neuropsychological assessment measures with gaboxadol treatment (RBANS List Learning). During the RBANS List Learning subtests, participants listen to a list of 10 words and repeat back as many as they can remember four times, for a maximum score of 40. Change scores were calculated by subtracting pre-dose words remembered from post-dose words remembered, with positive scores meaning an improvement in memory.

Pre-dose compared to 60 minutes post-dose on 4 study visits, up to day 42
To Investigate the Effect of Gaboxadol Treatment on Eye Tracking Assessments
Periodo de tiempo: Baseline compared to 60 minutes post-dose on 4 study visits, up to day 42

Change in eye tracking outcomes (60-90 minutes post-dose compared to pre-dose on percent viewing of social versus geometric scene

Baseline compared to 60 minutes post-dose on 4 study visits, up to day 42
To Investigate the Effect of Gaboxadol Treatment on Clinician-rated Measures
Periodo de tiempo: Post-dose on 4 study visits, up to day 42

Score on the Clinical Global Impressions - Improvement (CGI-I) scale, a clinician rating scale with "1" anchored to "very much improved" and "7" anchored to "very much worse."

Post-dose on 4 study visits, up to day 42
To Determine Whether FMRP Levels Predict Treatment Response
Periodo de tiempo: Baseline compared to 60 minutes post-dose on 4 study visits, up to day 42

Relationship between FMRP (Fragile X messenger ribonucleoprotein) level and degree of change (baseline/screen to post-dose) across measures

Baseline compared to 60 minutes post-dose on 4 study visits, up to day 42

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Colaboradores

Investigadores

  • Investigador principal: Cragi A Erickson, MD, Children's Hospital Medical Center, Cincinnati

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

29 de enero de 2024

Finalización primaria (Actual)

13 de mayo de 2025

Finalización del estudio (Actual)

24 de junio de 2025

Fechas de registro del estudio

Enviado por primera vez

8 de marzo de 2024

Primero enviado que cumplió con los criterios de control de calidad

19 de marzo de 2024

Publicado por primera vez (Actual)

28 de marzo de 2024

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

30 de septiembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

8 de septiembre de 2026

Última verificación

1 de julio de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • 2023-0795

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .